2024年度临床试验综述：有希望的康复之路

Infographic A Promising Rebound Selected Insights from the Annual ClinicalTrials Roundup: 2024 Edition Key Findings The rebound in clinical trial starts in 2023 signals a return to form after last year’s decline.However, the overall increase still fell short of gains made in pre-pandemic years, indicatingsome residual pressures on the clinical trial landscape. Phase I–III clinical trial activity by volume and growth Trialtrove captured 9,959 Phase I–III clinical trials investigating at least one drug and with a disclosed start date in 2023,an increase of 9.4% from the previous year and a recovery from 2022’s 12.5% decline in trial starts. Phase I–III clinical trial initiations by therapeutic area1 In 2023, oncology remained the lead therapeutic area by far, posting an increase of 9.5% from 2022. All therapeutic areasshowed growth except for infectious disease, which declined 14%. 1Trials that include multiple indications across different TAs will be counted for each targeted TA. As such, the sum of trial counts for the eight TAs will be higher thanthe total number of Phase I–III trials started in 2023. Trial counts for ID include activity from vaccines (infectious diseases), which is a separate TA module withinTrialtrove. For the purposes of this analysis, all ID activity has been combined into a single TA. Source: Trialtrove, June 2024 Top 10 diseases in Phase I–III clinical trial initiations Unspecified solid tumor remained the top disease for a second straight year. Non-small cell lung cancer took the No. 2spot from COVID-19, which slipped from second to eighth place in 2023. Rankings of top 10industry trial sponsors AstraZeneca wrested the No. 1 position back from Merck & Co., which fell to third place. Sino Biopharmaceutical jumpedto eighth, becoming the second Chinese pharma company to enter the top 10 after Jiangsu Hengrui Pharmaceuticals. A BrighterFuture? •Clinical Trials on the Rise: After a decline in 2022, clinical trial starts were onthe upswing in 2023.•Pandemic’s Influence Wanes: Pandemic-related fluctuations in clinical trialstarts appear to have eased up.•Pressures and Risks: The complex landscape still must face the effects ofthe industry’s adoption of new technologies, regulatory burdens, and drugpricing negotiations. Find out more about last year’s clinical trials trends and the forecast for thefuture in ourAnnual Clinical Trials Roundup: 2024 Edition white paper. Copyright © 2024 Pharma Intelligence UK Limited (Citeline), a Norstella company. Pharma Intelligence UK Limited is a company registered in Englandand Wales with company number 13787459 whose registered office is 3 More London Riverside, London SE1 2AQ